Remote Ischemic Conditoning (RIC)

Has been shown to significantly reduce Ischemia Reperfusion Injury (IRI) caused by cardiac events or through cardiac intervention






Learn more about RIC
The autoRIC™ Device

Automates RIC providing safe, convenient and accurate therapy delivery

Approved for use in Canada and EU

CAUTION: Investigational Device. Limited by United States law to Investigational Use.

Discover the autoRIC™ Device
RIC Clinical Research Trials

Over 100 completed and ongoing trials with more than 20,000 patients world-wide, zero adverse events reported









View RIC Clinical Trials
RIC Markets

$2 Billion Acute Market: Hospital and pre-hospital settings
$4-6 Billion Chronic Market: Heart Failure, Stroke, Home & Public settings








Explore RIC Markets

CellAegis Devices Inc. - Media Coverage

CellAegis Devices: 2012 Mind to Market Award Finalist

CellAegis autoRIC™ Device
European Hospital Early Adopter Program


Safe for your patient, Simple for you!
Preferred Consumables Pricing
Capital Costs Eliminated
Three-year warranty on Device(s)

Better Cath Lab Outcomes, Improved Clinical Benefit
pPCI: Infarct size reduction, MACE & mortality reduced
ePCI: Troponin and MACCE reductions
Coronary Angiogram/TAVR: Significant reduction in CI-AKI

For more information about the autoRIC™ Device or to inquire about our European Hospital Early Adopter Program:

Call us: 1-647-722-9601 Email us: info@cellaegisdevices.com